Autoimmune neurologic disease: long-term rituximab is well tolerated

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Patients with autoimmune neurologic disorders treated with rituximab (Rituxan) long term had low rates of infection-related adverse events.

Why this matters

  • Rituximab induces peripheral B-cell depletion.
  • Long-term experience with this antibody is limited.

Key results...